Eoin Flanagan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5583606/publications.pdf

Version: 2024-02-01

210 papers	9,636 citations	41258 49 h-index	49773 87 g-index
214 all docs	214 docs citations	214 times ranked	5324 citing authors

#	Article	IF	Citations
1	Optic chiasm involvement in AQP-4 antibodyâ€“positive NMO and MOG antibodyâ€“associated disorder. Multiple Sclerosis Journal, 2022, 28, 149-153.	1.4	24
2	Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Multiple Sclerosis and Related Disorders, 2022, 57, 103352.	0.9	19
3	Exposure to TNF inhibitors is rare at MOGAD presentation. Journal of the Neurological Sciences, 2022, 432, 120044.	0.3	7
4	LGI1 antibody encephalitis: acute treatment comparisons and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 309-315.	0.9	48
5	MRI with neck extension to diagnose cervical spondylotic myelopathy. Practical Neurology, 2022, 22, 162-163.	0.5	2
6	Populationâ€based incidence and clinicoâ€radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States. European Journal of Neurology, 2022, 29, 782-789.	1.7	11
7	Sustained, complete response to pexidartinib in a patient with <scp>CSF1R</scp>â€mutated Erdheimâ€“Chester disease. American Journal of Hematology, 2022, 97, 293-302.	2.0	9
8	OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103525.	0.9	36
9	Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110521.	0.5	1
10	CASPR2â€IgGâ€associated autoimmune seizures. Epilepsia, 2022, 63, 709-722.	2.6	14
11	Paraneoplastic myelopathy with amphiphysin autoantibodies and lobular breast carcinoma in situ. Journal of the Neurological Sciences, 2022, 432, 120086.	0.3	1
12	Understanding the etiology and epidemiology of meningitis and encephalitis: now and into the future. The Lancet Regional Health - Western Pacific, 2022, 20, 100380.	1.3	4
13	Teaching case in MS differential diagnosis: A Longstanding diagnosis of MS with severe disability. Multiple Sclerosis and Related Disorders, 2022, 59, 103540.	0.9	2
14	<scp>Antiâ€Neuronal</scp> Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1. Annals of Neurology, 2022, 91, 670-675.	2.8	17
15	Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations. Mayo Clinic Proceedings, 2022, 97, 547-559.	1.4	29
16	Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease. Frontiers in Neurology, 2022, 13, 866824.	1.1	16
17	Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. Neurotherapeutics, 2022, 19, 808-822.	2.1	14
18	Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. JAMA Neurology, 2022, 79, 518.	4.5	39

#	Article	IF	Citations
19	Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	29
20	Investigating the Immunopathogenic Mechanisms Underlying <scp>MOGAD</scp>. Annals of Neurology, 2022, 91, 299-300.	2.8	5
21	Inflammatory leukoencephalopathy mimicking hereditary disease. Neuroimmunology Reports, 2022, 2, 100092.	0.2	0
22	The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions. Multiple Sclerosis Journal, 2022, 28, 1710-1718.	1.4	1
23	Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldtâ€"Jakob disease and autoimmune encephalitis. European Journal of Neurology, 2022, 29, 2905-2912.	1.7	4
24	Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis. Brain Communications, 2022, 4, .	1.5	7
25	MOG-IgG1 and co-existence of neuronal autoantibodies. Multiple Sclerosis Journal, 2021, 27, 1175-1186.	1.4	29
26	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Multiple Sclerosis Journal, 2021, 27, 303-308.	1.4	64
27	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. Multiple Sclerosis Journal, 2021, 27, 667-673.	1.4	7
28	Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. Multiple Sclerosis Journal, 2021, 27, 630-635.	1.4	25
29	Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 895-902.	1.4	4
30	Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. Multiple Sclerosis and Related Disorders, 2021, 47, 102638.	0.9	20
31	Paraneoplastic Myeloneuropathies. Neurology, 2021, 96, e632-e639.	1.5	26
32	Acute flaccid myelitis: cause, diagnosis, and management. Lancet, The, 2021, 397, 334-346.	6.3	88
33	Inflammatory activity following motor progression due to critical CNS demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 1037-1045.	1.4	3
34	COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? â€" Commentary. Multiple Sclerosis Journal, 2021, 27, 976-977.	1.4	1
35	A multi-center case series of sarcoid optic neuropathy. Journal of the Neurological Sciences, 2021, 420, 117282.	0.3	13
36	Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions. Neurology: Clinical Practice, 2021, 11, e601-e611.	0.8	21

#	Article	IF	Citations
37	Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Communications, 2021, 3, fcaa233.	1.5	31
38	Reader Response: Clinical Significance of Anti-NMDAR Concurrent With Glial or Neuronal Surface Antibodies. Neurology, 2021, 96, 186-188.	1.5	1
39	Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199890.	1.5	15
40	Clinical spectrum of high-titre GAD65 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 645-654.	0.9	84
41	Myelitis and Other Autoimmune Myelopathies. CONTINUUM Lifelong Learning in Neurology, 2021, 27, 62-92.	0.4	16
42	Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis. Stroke, 2021, 52, 645-654.	1.0	9
43	<scp>Multiple Sclerosis</scp> Is Rare in Epsteinâ€“Barr Virusâ€“Seronegative Children with <scp>Central Nervous System</scp> Inflammatory Demyelination. Annals of Neurology, 2021, 89, 1234-1239.	2.8	16
44	Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 897-907.	0.9	66
45	Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 757-768.	0.9	227
46	Paraneoplastic disorders of the nervous system. Journal of Neurology, 2021, 268, 4899-4907.	1.8	6
47	Clinical and Radiologic Features, Pathology, and Treatment of BalÃ³ Concentric Sclerosis. Neurology, 2021, 97, e414-e422.	1.5	12
48	Clinical Utility of Antiretinal Antibody Testing. JAMA Ophthalmology, 2021, 139, 658.	1.4	18
49	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurology, 2021, 78, 741.	4.5	124
50	Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis. Neurology, 2021, 97, e1141-e1149.	1.5	27
51	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. Neurology, 2021, 97, e1097-e1109.	1.5	77
52	Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Frontiers in Neurology, 2021, 12, 673339.	1.1	40
53	003â€…Autoimmune encephalitis antibody biomarkers: frequency, age and sex associations. , 2021, , .		0
54	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. Neurology, 2021, 97, e1351-e1358.	1.5	25

#	Article	IF	Citations
55	Harry Lee Parker. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 701-719.	1.2	0
56	High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics. Multiple Sclerosis and Related Disorders, 2021, 56, 103253.	0.9	16
57	Teaching Video NeuroImages: Paroxysmal Dysarthria-Ataxia in Multiple Sclerosis. Neurology, 2021, 96, e2245-e2246.	1.5	5
58	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 384-390.	0.9	55
59	Evaluation and Management of Acute Myelopathy. Seminars in Neurology, 2021, 41, 511-529.	0.5	8
60	Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder. Multiple Sclerosis and Related Disorders, 2021, 56, 103310.	0.9	9
61	Myelin oligodendrocyte glycoprotein (MOG) antibodies in a patient with glioblastoma: Red flags for false positivity. Journal of Neuroimmunology, 2021, 361, 577743.	1.1	7
62	Uncommon inflammatory/immune-related myelopathies. Journal of Neuroimmunology, 2021, 361, 577750.	1.1	4
63	Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers. Annals of Clinical and Translational Neurology, 2021, 8, 425-439.	1.7	16
64	Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110487.	0.5	5
65	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110526.	0.5	11
66	Area postrema syndrome in autoimmune GFAP astrocytopathy. Multiple Sclerosis Journal, 2020, 26, 255-256.	1.4	4
67	Collapsin Response-Mediator Protein 5â€“Associated Retinitis, Vitritis, and Optic Disc Edema. Ophthalmology, 2020, 127, 221-229.	2.5	25
68	MOG-IgG myelitis coexisting with systemic lupus erythematosus in the post-partum setting. Multiple Sclerosis Journal, 2020, 26, 997-1000.	1.4	7
69	Optic neuritis in the era of biomarkers. Survey of Ophthalmology, 2020, 65, 12-17.	1.7	60
70	Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis. Neuro-Ophthalmology, 2020, 44, 1-4.	0.4	22
71	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. Multiple Sclerosis and Related Disorders, 2020, 37, 101487.	0.9	35
72	Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients. JAMA Neurology, 2020, 77, 257.	4.5	56

#	Article	IF	Citations
73	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgGâ€“associated disorders (MOGAD)?. Neurology, 2020, 94, 85-88.	1.5	30
74	Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. American Journal of Ophthalmology, 2020, 220, 110-114.	1.7	48
75	Enlarging Perivascular Spaces Following Radiation Therapy in the Brain: A Report of 2 Cases and Literature Review. World Neurosurgery, 2020, 138, 436-439.	0.7	4
76	Holmes tremor with peri-rolandic demyelinating lesions. Neurology, 2020, 96, 10.1212/WNL.0000000000011235.	1.5	1
77	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. Clinical Chemistry, 2020, 66, 1496-1509.	1.5	41
78	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. JAMA Neurology, 2020, 77, 1420.	4.5	109
79	Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgGâ€“Associated Disorders. JAMA Neurology, 2020, 77, 1572.	4.5	14
80	Unfavorable outcome in highly relapsing MOGAD encephalitis. Journal of the Neurological Sciences, 2020, 418, 117088.	0.3	8
81	Expanded genetic insight and clinical experience of DNMT1-complex disorder. Neurology: Genetics, 2020, 6, e456.	0.9	7
82	Imaging Review of Paraneoplastic Neurologic Syndromes. American Journal of Neuroradiology, 2020, 41, 2176-2187.	1.2	37
83	Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin Gâ€“Associated Disorder. JAMA Neurology, 2020, 77, 1575.	4.5	52
84	Neurologic autoimmunity and immune checkpoint inhibitors. Neurology, 2020, 95, e2442-e2452.	1.5	94
85	Spinal arteriovenous fistula's often misdiagnosed as myelitis; can we stem the flow?. Journal of the Neurological Sciences, 2020, 413, 116868.	0.3	4
86	Unilateral Cortical Fluid-Attenuated Inversion Recoveryâ€“Hyperintense Lesions in Anti-Myelin Oligodendrocyte Glycoproteinâ€“Associated Encephalitis With Seizures (FLAMES): An Under-recognized Entity. Pediatric Neurology, 2020, 110, 99-100.	1.0	2
87	Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	29
88	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology, 2020, 95, e111-e120.	1.5	140
89	Spinal cord transient ischemic attack. Neurology: Clinical Practice, 2020, 10, 480-483.	0.8	6
90	Use of diffusion-weighted imaging to distinguish seizure-related change from limbic encephalitis. Journal of Neurology, 2020, 267, 3337-3342.	1.8	15

#	Article	IF	Citations
91	FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis With Seizures (FLAMES): Is immunotherapy always needed to put out the fire?. Multiple Sclerosis and Related Disorders, 2020, 44, 102283.	0.9	15
92	International multicenter examination of MOG antibody assays. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	180
93	Unilateral Leptomeningeal Enhancement in Myelin Oligodendrocyte Glycoprotein Immunoglobulin Gâ€“Associated Disease. JAMA Neurology, 2020, 77, 648.	4.5	22
94	Autoimmune psychosis. Lancet Psychiatry,the, 2020, 7, 122.	3.7	4
95	The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathologica, 2020, 139, 875-892.	3.9	205
96	Paraneoplastic Disorders of the Nervous System. CONTINUUM Lifelong Learning in Neurology, 2020, 26, 1602-1628.	0.4	7
97	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 488-490.	0.9	54
98	Testing for Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG) in typical MS. Multiple Sclerosis and Related Disorders, 2019, 35, 34-35.	0.9	2
99	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. Neurology, 2019, 93, e414-e420.	1.5	26
100	Optical coherence tomography is highly sensitive in detecting prior optic neuritis. Neurology, 2019, 92, e527-e535.	1.5	56
101	Author response: Clinical Reasoning: A 56-year-old woman with acute vertigo and diplopia. Neurology, 2019, 92, 249-249.	1.5	0
102	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	4.9	110
103	A multicenter comparison of MOG-IgG cell-based assays. Neurology, 2019, 92, e1250-e1255.	1.5	135
104	Diagnosis and Management of Autoimmune Dementia. Current Treatment Options in Neurology, 2019, 21, 11.	0.7	16
105	Isolated recurrent myelitis in a persistent MOG positive patient. Multiple Sclerosis and Related Disorders, 2019, 30, 163-164.	0.9	3
106	Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder. Neurology, 2019, 92, 343-344.	1.5	4
107	Reader response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology, 2019, 93, 722-723.	1.5	1
108	Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e620.	3.1	2

#	Article	IF	Citations
109	Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2018-320243.	0.9	23
110	Unilateral motor progression in MS. Neurology, 2019, 93, e628-e634.	1.5	22
111	Glial Fibrillary Acidic Protein (GFAP) Autoimmunity in the Setting of Seropositive Rheumatoid Arthritis Treated With Etanercept. Neurologist, 2019, 24, 152-154.	0.4	4
112	Neurochondrin neurological autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	28
113	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurology, 2019, 76, 301.	4.5	243
114	Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria. JAMA Neurology, 2019, 76, 56.	4.5	134
115	Neuromyelitis Optica Spectrum Disorder and Other Nonâ€“Multiple Sclerosis Central Nervous System Inflammatory Diseases. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 815-844.	0.4	40
116	Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4â€“IgG in Patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmology, 2018, 136, 419.	1.4	104
117	A practical approach to the diagnosis of spinal cord lesions. Practical Neurology, 2018, 18, 187-200.	0.5	34
118	Clinical Reasoning: A 30-year-old man with headache and sleep disturbance. Neurology, 2018, 90, e1535-e1540.	1.5	4
119	Clinical Reasoning: A 56-year-old woman with acute vertigo and diplopia. Neurology, 2018, 90, 748-752.	1.5	8
120	Reply to â€œepidemiology of autoimmune versus infectious encephalitisâ€• Annals of Neurology, 2018, 83, 1038-1038.	2.8	2
121	Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies. Mayo Clinic Proceedings, 2018, 93, 1299-1304.	1.4	24
122	Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Annals of Neurology, 2018, 83, 166-177.	2.8	479
123	Trident sign trumps Aquaporin-4-IgG ELISA in diagnostic value in a case of longitudinally extensive transverse myelitis. Multiple Sclerosis and Related Disorders, 2018, 23, 7-8.	0.9	18
124	Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. JAMA Neurology, 2018, 75, 892.	4.5	17
125	Elevated <scp>LGI</scp>1â€IgG <scp>CSF</scp> index predicts worse neurological outcome. Annals of Clinical and Translational Neurology, 2018, 5, 646-650.	1.7	35
126	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. Ophthalmology, 2018, 125, 1628-1637.	2.5	108

#	Article	IF	Citations
127	Spinal cord infarction: Clinical and imaging insights from the periprocedural setting. Journal of the Neurological Sciences, 2018, 388, 162-167.	0.3	28
128	Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibodyâ€“Positive Meningoencephalitis. Journal of Neuro-Ophthalmology, 2018, 38, 276-281.	0.4	36
129	Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology, 2018, 90, e103-e110.	1.5	86
130	Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. Neurology, 2018, 90, e96-e102.	1.5	82
131	A path to understanding autoimmune GFAP astrocytopathy. European Journal of Neurology, 2018, 25, 421-422.	1.7	19
132	Breast cancer-related paraneoplastic neurologic disease. Breast Cancer Research and Treatment, 2018, 167, 771-778.	1.1	20
133	A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. Multiple Sclerosis and Related Disorders, 2018, 19, 115-117.	0.9	9
134	Area postrema syndrome. Neurology, 2018, 91, e1642-e1651.	1.5	129
135	Population-based study of â€œno evident disease activityâ€•in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e495.	3.1	6
136	Unique Gadolinium Enhancement Pattern in Spinal Dural Arteriovenous Fistulas. JAMA Neurology, 2018, 75, 1542.	4.5	44
137	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurology, The, 2018, 17, 498-499.	4.9	2
138	Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1â€¯year. Journal of Neuroimmunology, 2018, 321, 157-163.	1.1	136
139	LGI1 and CASPR2 neurological autoimmunity in children. Annals of Neurology, 2018, 84, 473-480.	2.8	53
140	Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. American Journal of Ophthalmology, 2018, 195, 8-15.	1.7	295
141	Spontaneous posterior spinal artery infarction. Neurology, 2018, 91, 414-417.	1.5	16
142	Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. Multiple Sclerosis Journal, 2018, 24, 1445-1452.	1.4	18
143	Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. Journal of Neuroimmunology, 2018, 323, 62-72.	1.1	68
144	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgGâ€“Associated Disorders. JAMA Neurology, 2018, 75, 1355.	4.5	286

#	Article	IF	Citations
145	Diagnostic and Therapeutic Approach to Autoimmune Neurologic Disorders. Seminars in Neurology, 2018, 38, 392-402.	0.5	22
146	Autoimmune and Paraneoplastic Myelopathies. Seminars in Neurology, 2018, 38, 278-289.	0.5	21
147	Posttransplant autoimmune encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e497.	3.1	24
148	Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2017, 74, 359.	4.5	38
149	Paroxysmal sneezing in NMOSD: Further evidence of the localization of the human sneeze center. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e303.	3.1	3
150	Glial fibrillary acidic protein immunoglobulin <scp>G</scp> as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Annals of Neurology, 2017, 81, 298-309.	2.8	366
151	Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 218-225.	0.9	53
152	Myelitis in neuromyelitis optica spectrum disorder: The long and the short of it. Multiple Sclerosis Journal, 2017, 23, 360-361.	1.4	6
153	Elsberg syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e355.	3.1	55
154	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e343.	3.1	55
155	Expanded phenotypes and outcomes among 256 <scp>LGI</scp>1/<scp>CASPR</scp>2â€<scp>I</scp>g<scp>G</scp>â€“positive patients. Annals of Neurology, 2017, 82, 79-92.	2.8	242
156	Clinical commentary on â€˜Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new casesâ€™, by Wang et al.. Multiple Sclerosis Journal, 2017, 23, 1954-1955.	1.4	0
157	Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia, 2017, 58, 1181-1189.	2.6	120
158	Diagnosis and management of spinal cord emergencies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 140, 319-335.	1.0	18
159	Striking basal ganglia imaging abnormalities in LGI1 ab faciobrachial dystonic seizures. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e336.	3.1	20
160	Utility of extension views in spondylotic myelopathy mimicking transverse myelitis. Multiple Sclerosis and Related Disorders, 2017, 11, 62-64.	0.9	11
161	NEDA treatment target? No evident disease activity as an actionable outcome in practice. Journal of the Neurological Sciences, 2017, 383, 31-34.	0.3	24
162	Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. Multiple Sclerosis Journal, 2017, 23, 1808-1817.	1.4	35

#	Article	IF	Citations
163	B-cellâ€“targeted therapies in relapsing forms of MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e405.	3.1	10
164	Dacrystic seizures: A cry for help. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e372.	3.1	3
165	Clinical Reasoning: A 54-year-old woman with dementia, myoclonus, and ataxia. Neurology, 2017, 89, e7-e12.	1.5	5
166	Epidemiology of aquaporinâ€4 autoimmunity and neuromyelitis optica spectrum. Annals of Neurology, 2016, 79, 775-783.	2.8	263
167	Autoimmune myelopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 327-351.	1.0	42
168	Autoimmune dementia and encephalopathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 247-267.	1.0	16
169	Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology, 2016, 87, 743-744.	1.5	94
170	Progressive solitary sclerosis. Neurology, 2016, 87, 1713-1719.	1.5	59
171	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Annals of Neurology, 2016, 79, 437-447.	2.8	148
172	Neuromyelitis optica spectrum initially diagnosed as antiphospholipid antibody myelitis. Journal of the Neurological Sciences, 2016, 361, 204-205.	0.3	7
173	Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia. Neurocase, 2016, 22, 55-59.	0.2	11
174	IgG4â€related (neurologic) disease: diagnostic challenges, clinical clues and expanding spectrum. International Journal of Rheumatic Diseases, 2015, 18, 807-809.	0.9	4
175	Short Myelitis Lesions in Aquaporin-4-IgGâ€“Positive Neuromyelitis Optica Spectrum Disorders. JAMA Neurology, 2015, 72, 81.	4.5	209
176	Conjunctival biopsy to diagnose neurosarcoidosis in patients with inflammatory nervous system disease of unknown etiology. Neurology: Clinical Practice, 2015, 5, 216-223.	0.8	9
177	Dominant Frontotemporal Dementia Mutations in 140 Cases of Primary Progressive Aphasia and Speech Apraxia. Dementia and Geriatric Cognitive Disorders, 2015, 39, 281-286.	0.7	32
178	Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. Sleep Medicine, 2015, 16, 1502-1510.	0.8	45
179	Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e161.	3.1	163
180	Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy. Neurology: Clinical Practice, 2015, 5, 175-177.	0.8	21

#	Article	IF	Citations
181	Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults. JAMA Neurology, 2015, 72, 1304.	4.5	86
182	Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotility. Neurogastroenterology and Motility, 2014, 26, 1285-1297.	1.6	58
183	Clinical Reasoning: A 55-year-old man with weight loss, ataxia, and foot drop. Neurology, 2014, 82, e214-9.	1.5	3
184	Fulminant cerebellitis with radiological recurrence in an adult patient with Crohn's disease. Journal of the Neurological Sciences, 2014, 336, 247-250.	0.3	8
185	Neuromyelitis Optica Spectrum Disorders. Current Neurology and Neuroscience Reports, 2014, 14, 483.	2.0	42
186	Dementia in MS complicated by coexistent Alzheimer disease. Neurology: Clinical Practice, 2014, 4, 226-230.	0.8	13
187	Anterior spinal artery infarction causing man-in-the-barrel syndrome. Neurology: Clinical Practice, 2014, 4, 268-269.	0.8	9
188	Specific pattern of gadolinium enhancement in spondylotic myelopathy. Annals of Neurology, 2014, 76, 54-65.	2.8	89
189	In replyâ€"Sensitivity of [18F]-fluorodeoxyglucoseâ€"Positron Emission Tomography in Patients With Active Myelopathy. Mayo Clinic Proceedings, 2014, 89, 859.	1.4	2
190	Paraneoplastic Myelopathy. Neurologic Clinics, 2013, 31, 307-318.	0.8	43
191	[18F]-Fluorodeoxyglucoseâ€"Positron Emission Tomography in Patients With Active Myelopathy. Mayo Clinic Proceedings, 2013, 88, 1204-1212.	1.4	37
192	Amyloidâ€"Î²-related angiitis presenting as a uveomeningeal syndrome. Neurology, 2013, 81, 1796-1798.	1.5	11
193	SjÃ¶gren's syndrome with trigeminal neuropathy: motor involvement. Practical Neurology, 2013, 13, 340-342.	0.5	7
194	Primary leptomeningeal lymphoma. Neurology, 2013, 81, 1690-1696.	1.5	70
195	Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder. Neurology: Clinical Practice, 2013, 3, 448-451.	0.8	10
196	Adult-onset autosomal dominant leukodystrophy presenting with REM sleep behavior disorder. Neurology, 2013, 80, 118-120.	1.5	13
197	Teaching Neuro Images : â€œPancake-likeâ€•gadolinium enhancement suggests compressive myelopathy due to spondylosis. Neurology, 2013, 80, e229.	1.5	11
198	Paraneoplastic lower motor neuronopathy associated with Hodgkin lymphoma. Muscle and Nerve, 2012, 46, 823-827.	1.0	38

#	Article	IF	Citations
199	Secondary intramedullary spinal cord non-Hodgkinâ€™s lymphoma. Journal of Neuro-Oncology, 2012, 107, 575-580.	1.4	23
200	Amiodaroneâ€associated neuromyopathy: a report of four cases. European Journal of Neurology, 2012, 19, e50-1.	1.7	12
201	Paraneoplastic isolated myelopathy. Neurology, 2011, 76, 2089-2095.	1.5	187
202	Autoimmune Myelopathies. CONTINUUM Lifelong Learning in Neurology, 2011, 17, 776-799.	0.4	8
203	Foot and ankle surgeryâ€”The Achilles heel of medical students and doctors. Foot, 2011, 21, 109-113.	0.4	9
204	Autoimmune Encephalopathy. Seminars in Neurology, 2011, 31, 144-157.	0.5	38
205	Primary intramedullary spinal cord lymphoma. Neurology, 2011, 77, 784-791.	1.5	101
206	Addition of Magnetic Resonance Imaging to Computed Tomography and Sensitivity to Blood in Pituitary Apoplexy. Archives of Neurology, 2011, 68, 1336.	4.9	8
207	Attitudes of US medical trainees towards neurology education: "Neurophobia" - a global issue. BMC Medical Education, 2010, 10, 49.	1.0	161
208	Autoimmune Dementia: Clinical Course and Predictors of Immunotherapy Response. Mayo Clinic Proceedings, 2010, 85, 881-897.	1.4	158
209	â€˜Neurophobiaâ€™â€“ attitudes of medical students and doctors in Ireland to neurological teaching. European Journal of Neurology, 2007, 14, 1109-1112.	1.7	119
210	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Frontiers in Neurology, 0, 13, .	1.1	84